SSA timeline
Every SSA batch the index holds, newest manufacture date first, with the supplier's declared purity beside the median of the index's independent observations of the same lot.
| Lot | Compound | Manufactured | Quarter | Tests | Independent median | Spread (pp) | COA purity | Divergence (pp) | |
|---|---|---|---|---|---|---|---|---|---|
| SSA-2605-G6781 | Mazdutide | 07 May 2026 | 2026-Q2 | 9 | 98.74 | 0.99 | 99.41 | +0.67 | |
| SSA-2604-L7628 | Semax | 17 Apr 2026 | 2026-Q2 | 2 | 98.57 | 0.54 | 99.03 | +0.46 | |
| SSA-2604-V7620 | GHK-Cu | 10 Apr 2026 | 2026-Q2 | 2 | 98.16 | 0.39 | 98.66 | +0.50 | |
| SSA-2604-G7599 | Ipamorelin | 06 Apr 2026 | 2026-Q2 | 1 | 99.35 | n<2 | 100.00 | +0.65 | |
| SSA-2603-C6950 | Enclomiphene citrate | 04 Mar 2026 | 2026-Q2 | 2 | 97.83 | 0.19 | 99.00 | +1.17 | |
| SSA-2601-T7702 | Retatrutide | 26 Jan 2026 | 2026-Q1 | 8 | 98.80 | 1.28 | 99.20 | +0.40 | |
| SSA-2601-Y7541 | Triptorelin | 15 Jan 2026 | 2026-Q2 | 2 | 99.24 | 0.08 | 99.01 | -0.23 | |
| SSA-2601-N6752 | BPC-157 | 09 Jan 2026 | 2026-Q2 | 6 | 98.13 | 1.00 | 98.09 | -0.04 | |
| SSA-2512-C6732 | CJC-1295 with DAC | 17 Dec 2025 | 2026-Q1 | 2 | 98.04 | 0.10 | 98.65 | +0.61 | |
| SSA-2511-W7415 | MOTS-c | 10 Nov 2025 | 2026-Q2 | 6 | 98.17 | 1.20 | 98.41 | +0.24 | |
| SSA-2511-N7115 | Tirzepatide | 04 Nov 2025 | 2026-Q2 | 2 | 98.04 | 0.85 | 97.99 | -0.05 | |
| SSA-2510-E6502 | Retatrutide | 26 Oct 2025 | 2025-Q4 | 4 | 97.02 | 1.03 | 97.04 | +0.02 | |
| SSA-2510-C7247 | Semaglutide | 02 Oct 2025 | 2025-Q4 | 10 | 98.91 | 1.63 | 98.89 | -0.02 | |
| SSA-2509-J7266 | Semaglutide | 10 Sep 2025 | 2025-Q4 | 3 | 97.33 | 0.39 | 97.97 | +0.64 | |
| SSA-2509-Y7113 | IGF-1 DES (1-3) | 08 Sep 2025 | 2025-Q4 | 1 | 97.65 | n<2 | 98.51 | +0.86 | |
| SSA-2508-P6816 | Humanin (HNG) | 26 Aug 2025 | 2025-Q3 | 2 | 99.07 | 0.46 | 99.15 | +0.08 | |
| SSA-2508-P6053 | Tirzepatide | 25 Aug 2025 | 2026-Q1 | 6 | 97.71 | 1.73 | 97.87 | +0.16 | |
| SSA-2508-B6325 | Vilon | 18 Aug 2025 | 2025-Q3 | 11 | 99.15 | 1.32 | 99.34 | +0.19 | |
| SSA-2508-N7223 | Retatrutide | 12 Aug 2025 | 2025-Q3 | 7 | 97.49 | 1.07 | 97.83 | +0.34 | |
| SSA-2508-Y6894 | Semaglutide | 09 Aug 2025 | 2025-Q3 | 5 | 98.51 | 1.32 | 98.46 | -0.05 | |
| SSA-2507-Y8342 | PT-141 (Bremelanotide) | 31 Jul 2025 | 2025-Q3 | 1 | 98.37 | n<2 | 99.08 | +0.71 | |
| SSA-2507-W7338 | Retatrutide | 14 Jul 2025 | 2025-Q3 | 6 | 98.18 | 0.92 | 98.26 | +0.08 | |
| SSA-2507-B7861 | KPV | 06 Jul 2025 | 2025-Q4 | 1 | 99.06 | n<2 | 99.08 | +0.02 | |
| SSA-2506-X6030 | L-Glutathione (reduced) | 05 Jun 2025 | 2025-Q3 | 4 | 98.58 | 0.85 | 99.54 | +0.96 | |
| SSA-2505-D7439 | GHRP-2 | 24 May 2025 | 2025-Q2 | 6 | 99.22 | 0.58 | 98.97 | -0.25 | |
| SSA-2505-J7223 | BPC-157 | 13 May 2025 | 2025-Q3 | 4 | 99.04 | 0.56 | 99.22 | +0.18 | |
| SSA-2505-U6896 | PEG-MGF | 08 May 2025 | 2025-Q4 | 12 | 95.86 | 0.79 | 96.56 | +0.70 | |
| SSA-2504-M8130 | Gonadorelin | 05 Apr 2025 | 2025-Q3 | 2 | 99.93 | 0.00 | 99.90 | -0.03 | |
| SSA-2504-T7815 | L-Carnosine | 01 Apr 2025 | 2025-Q2 | 3 | 98.42 | 1.11 | 99.34 | +0.92 | |
| SSA-2503-S7755 | MOTS-c | 31 Mar 2025 | 2025-Q3 | 7 | 99.39 | 0.72 | 99.39 | 0.00 | |
| SSA-2502-D7115 | Tirzepatide | 11 Feb 2025 | 2025-Q3 | 4 | 97.58 | 1.13 | 98.00 | +0.42 | |
| SSA-2502-U6796 | Semaglutide | 10 Feb 2025 | 2025-Q3 | 4 | 97.78 | 0.93 | 97.83 | +0.05 | |
| SSA-2501-W8087 | L-Glutathione (reduced) | 19 Jan 2025 | 2025-Q1 | 13 | 99.12 | 1.07 | 99.40 | +0.28 | |
| SSA-2501-N6217 | Melanotan II | 19 Jan 2025 | 2025-Q1 | 6 | 98.59 | 1.22 | 99.37 | +0.78 | |
| SSA-2501-M6043 | MOTS-c | 15 Jan 2025 | 2025-Q1 | 14 | 97.93 | 1.77 | 97.90 | -0.03 | |
| SSA-2501-N6670 | 5-Amino-1MQ | 04 Jan 2025 | 2025-Q2 | 1 | 99.17 | n<2 | 99.90 | +0.73 | |
| SSA-2412-Y7639 | Semaglutide | 22 Dec 2024 | 2025-Q2 | 8 | 97.67 | 1.31 | 97.55 | -0.12 | |
| SSA-2410-G6381 | Semax | 12 Oct 2024 | 2024-Q4 | 9 | 98.30 | 1.13 | 98.60 | +0.30 | |
| SSA-2409-X7050 | Sermorelin | 10 Sep 2024 | 2025-Q1 | 1 | 98.45 | n<2 | 98.38 | -0.07 | |
| SSA-2408-F7210 | Glucagon | 27 Aug 2024 | 2024-Q3 | 7 | 98.91 | 1.56 | 98.80 | -0.11 | |
| SSA-2408-G7000 | SS-31 (Elamipretide) | 02 Aug 2024 | 2024-Q3 | 5 | 97.72 | 0.45 | 97.89 | +0.17 | |
| SSA-2407-L6907 | Mazdutide | 09 Jul 2024 | 2024-Q4 | 8 | 97.85 | 0.79 | 98.02 | +0.17 | |
| SSA-2407-L6253 | Thymosin α1 | 05 Jul 2024 | 2024-Q3 | 4 | 98.63 | 0.90 | 98.83 | +0.20 | |
| SSA-2406-H7478 | TB-500 | 01 Jun 2024 | 2024-Q4 | 12 | 98.60 | 0.79 | 98.52 | -0.08 | |
| SSA-2405-G6398 | Retatrutide | 26 May 2024 | 2024-Q3 | 12 | 97.54 | 1.29 | 97.98 | +0.44 | |
| SSA-2404-U7946 | Ipamorelin | 09 Apr 2024 | 2024-Q3 | 14 | 98.18 | 1.69 | 98.50 | +0.32 | |
| SSA-2403-F6661 | IGF-1 DES (1-3) | 28 Mar 2024 | 2024-Q2 | 8 | 99.46 | 1.42 | 98.92 | -0.54 | |
| SSA-2403-B6820 | Semaglutide | 18 Mar 2024 | 2024-Q2 | 6 | 98.60 | 1.00 | 99.57 | +0.97 | |
| SSA-2403-F6387 | PT-141 (Bremelanotide) | 14 Mar 2024 | 2024-Q3 | 1 | 97.87 | n<2 | 98.38 | +0.51 | |
| SSA-2403-V6258 | LL-37 | 12 Mar 2024 | 2024-Q2 | 12 | 98.31 | 1.33 | 98.74 | +0.43 | |
| SSA-2401-E8185 | BPC-157 | 26 Jan 2024 | 2024-Q2 | 5 | 99.61 | 0.64 | 99.87 | +0.26 | |
| SSA-2312-V7746 | Tirzepatide | 20 Dec 2023 | 2024-Q2 | 3 | 98.04 | 0.36 | 98.18 | +0.14 |